Edwards Lifesciences (EW) Cash from Operations (2009 - 2026)

Edwards Lifesciences has reported Cash from Operations for 18 years, with the latest figure at 43800000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 84.38% year-over-year to 43800000.0; the trailing twelve-month figure through Mar 2026 stood at 1358600000.0 (up 55.06% YoY), and the FY2025 full-year result was 1595200000.0, up 194.15% from the prior year.
• Cash from Operations for Q1 2026 stood at 43800000.0, down from 450900000.0 in the prior quarter.
• The five-year high for Cash from Operations was 573700000.0 in Q3 2025, with the low at 127500000.0 in Q4 2024.
• Average Cash from Operations over 5 years is 252664705.88, with a median of 293300000.0 recorded in 2022.
• Peak annual rise in Cash from Operations reached 1005.65% in 2024, while the deepest fall reached 193.34% in 2024.
• Tracing EW's Cash from Operations over 5 years: stood at 282800000.0 in 2022, then plunged by 51.7% to 136600000.0 in 2023, then slumped by 193.34% to 127500000.0 in 2024, then surged by 453.65% to 450900000.0 in 2025, then tumbled by 90.29% to 43800000.0 in 2026.
• The last three Cash from Operations figures came in at 43800000.0 (Q1 2026), 450900000.0 (Q4 2025), and 573700000.0 (Q3 2025), per Business Quant data.

Peer Comparison